Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,414 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $11,414 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $8,360 | 2 | Regeneron Pharmaceuticals, Inc. ($8,360) |
| 2020 | $2,373 | 4 | Regeneron Pharmaceuticals, Inc. ($2,373) |
| 2019 | $681.08 | 2 | Regeneron Pharmaceuticals, Inc. ($681.08) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/14/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $4,179.91 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 07/14/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $4,179.91 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 12/06/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $1,159.17 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 10/02/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $665.45 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 06/11/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $459.42 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 04/24/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $89.03 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 12/09/2019 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $532.72 | Research |
| Study: REGN1979-Clinical Development Program | ||||||
| 10/02/2019 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $148.36 | Research |
| Study: REGN1979-Clinical Development Program | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| REGN1979-CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $10,733 | 6 |
| REGN1979-Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $681.08 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 77 | 239 | $71,925 | $21,263 |
| 2022 | 5 | 185 | 395 | $132,358 | $33,454 |
| 2021 | 5 | 185 | 386 | $141,734 | $35,701 |
| 2020 | 4 | 153 | 262 | $46,179 | $16,404 |
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 141 | $47,235 | $14,206 | 30.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 82 | $19,106 | $5,493 | 28.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 16 | $5,584 | $1,564 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 168 | $56,280 | $14,704 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 75 | 123 | $40,098 | $9,767 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 27 | 48 | $23,088 | $5,783 | 25.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 43 | $10,019 | $2,620 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 13 | $2,873 | $580.52 | 20.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 137 | $65,445 | $16,500 | 25.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 80 | 150 | $48,636 | $11,832 | 24.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 47 | $15,745 | $4,256 | 27.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 39 | $9,087 | $2,457 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 13 | $2,821 | $656.26 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 74 | 163 | $25,440 | $10,486 | 41.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 27 | $9,261 | $2,472 | 26.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 39 | 46 | $5,290 | $1,800 | 34.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 26 | $6,188 | $1,647 | 26.6% |
About Dr. Robin Marie Joyce, M.D
Dr. Robin Marie Joyce, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659318350.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robin Marie Joyce, M.D has received a total of $11,414 in payments from pharmaceutical and medical device companies, with $8,360 received in 2022. These payments were reported across 8 transactions from 1 company. The most common payment nature is "" ($11,414).
As a Medicare-enrolled provider, Joyce has provided services to 600 Medicare beneficiaries, totaling 1,282 services with total Medicare billing of $106,822. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 06/01/2006
- Last Updated 06/07/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659318350
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795